期刊
FRONTIERS IN PHARMACOLOGY
卷 13, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2022.1061178
关键词
bioavailability; topically applied dermal drug products; verification study; cutaneous PK; dermal penetration; PK-based BE study; interstitial fluid; systemic redistribution
资金
- Food and Drug Administration
- [1U01FD004946]
- [1U01FD005861]
Topically applied drug products in the US have seen significant price increases due to a lack of generic options. Generic drug development is limited by high costs and risks associated with proving bioequivalence. Cutaneous PK-based studies offer a cost-effective alternative to clinical endpoint studies.
Topically applied drug products have experienced an extraordinary price increase in the United States, mostly due to a lack of generic products. Generic drug development is hindered by high costs and risks associated with clinical endpoint studies required to show bioequivalence (BE) of prospective generic products relative to their reference products. There is a continued need for cost- and time-efficient alternatives to clinical endpoint studies to determine BE of topically applied dermal drug products. Cutaneous PK-based BE studies present such an alternative and dOFM (dermal open flow microperfusion) has already been successfully used in several verifications studies to show an accurate and sensitive assessment of the rate and extent at which drugs become available in the skin. dOFM technology is discussed as well as the dOFM setup of clinical pilot and main studies to achieve BE assessment with a minimum number of participants and an outlook is given on the use of dOFM technology for other drug products.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据